Ad
related to: merck+%26+co
Search results
Merck acquires EyeBio in up to $3B deal By Proactive Investors
Investing.com· 2 days agoMerck & Co Inc (NYSE:MRK, ETR:6MK) announced it is acquiring Eyebio, a privately held...
Merck & Co. sees clear vision to new ophthalmology assets with $3B EyeBio buy
FierceBiotech· 3 days agoMerck & Co. is focusing in on eye diseases with the $3 billion acquisition of ophthalmology-focused Eyebiotech. Merck will take on a pipeline of vision ...
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
WHTC 1450 Holland· 3 days ago(Reuters) -Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company...
Merck to buy eye drug developer for $1.3B
BioPharma Dive via Yahoo Finance· 3 days agoAn acquisition of EyeBio will hand Merck a treatment for diabetic macular edema and age-related macular degeneration that’s ready for pivotal testing.
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 3 days agoJeito Capital announces the acquisition by Merck & Co (NYSE: MRK)of its portfolio company EyeBio for a potential value of $3 billion This acquisition reflects ...
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
Zacks via Yahoo Finance· 2 days agoMerck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a...
Merck Announces Third-Quarter 2024 Dividend
Morningstar· 3 days agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common ...
Hedge Funds Are Loading Up On This Dividend Stock
Benzinga via Yahoo Finance· 5 days agoThe markets are adjusting to the high interest rates environment, with all the major US stock indices reporting strong gains in May 2024. However, even...
Merck On Track for Largest Percent Decrease Since October 2023 — Data Talk
Morningstar· 4 days agoMerck & Co., Inc. (MRK) is currently at $126.30, down $3.19 or 2.46% --Would be lowest close since April 19, 2024, when it closed at $125.78 --On pace for ...
Roche’s Sabry retires; Duchenne drug fails confirmatory test
BioPharma Dive via Yahoo Finance· 4 days agoThe veteran executive will be replaced by Boris Zaïtra. Elsewhere, Nippon Shinyaku shared negative...